TRCT
PTHS

Tower Research Capital (TRC)’s Pelthos Therapeutics PTHS Stock Holding History

Tower Research Capital (TRC)’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-827
Closed -$23.2K – 5687
2025
Q3 		$23.2K Buy
827
+818
+9,089% +$19.9K ﹤0.01% 3176
2025
Q2 		$107 Sell
9
-248
-96% -$2.99K ﹤0.01% 5141
2025
Q1 		$3.64K Buy
257
+232
+928% +$3.97K ﹤0.01% 4374
2024
Q4 		$162 Sell
25
-1
-4% -$7 ﹤0.01% 5406
2024
Q3 		$184 Buy
26
+25
+2,500% +$244 ﹤0.01% 5439
2024
Q2 		$8 Buy
+1
New +$17 ﹤0.01% 5604

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tower Research Capital (TRC)'s PTHS Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Pelthos Therapeutics (PTHS) in Q4 2025, closing a stake of 827 shares — an estimated $23.2K sold.

Tower Research Capital (TRC) first reported a position in PTHS in Q2 2024 and held it in 6 quarters. The position peaked at $23.2K in Q3 2025. 15 funds tracked by Wall St. Rank hold PTHS as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Pelthos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 827 Pelthos Therapeutics shares in Q4 2025, an estimated $23.2K.
  • Tower Research Capital (TRC) first reported a position in Pelthos Therapeutics in Q2 2024 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Pelthos Therapeutics position peaked at $23.2K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.